Product
Convalescent Plasma
8 clinical trials
9 indications
Indication
COVID-19Indication
SARS-CoV-2Indication
Coronavirus InfectionIndication
Complication of Mechanical VentilationIndication
Respiratory FailureIndication
Severe Acute Respiratory Syndrome (SARS)Indication
Immunocompromised HostIndication
Plasma TherapyIndication
Anti-CD20 TherapyClinical trial
Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 InfectionStatus: Terminated, Estimated PCD: 2021-04-29
Clinical trial
Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 InfectionStatus: Terminated, Estimated PCD: 2023-04-26
Clinical trial
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19Status:
Clinical trial
Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19Status: Completed, Estimated PCD: 2020-07-31
Clinical trial
A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT TrialStatus: Active (not recruiting), Estimated PCD: 2022-04-09
Clinical trial
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy: Clinical Course and Convalescent Plasma TherapyStatus: Completed, Estimated PCD: 2023-01-15
Clinical trial
Assessment of the Safety and Efficacy of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above IllnessStatus: Completed, Estimated PCD: 2021-06-30